Levilactobacillus brevis is a type of bacteria found in fermented foods like sourdough bread and some beers and wines. It's used as a starter culture to help make these foods. It's a type of lactic acid bacteria.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Levilactobacillus brevis is a lactic acid bacterium, a microbe that ferments sugars into lactic acid. Until 2020 it was classified as Lactobacillus brevis, and many products and studies still use that name. It is used to ferment sourdough, animal feed (silage) and some sour beers and wines. As a supplement, L. brevis is sold as a probiotic, meaning live microbes intended to benefit health. Most research in people has focused on the mouth: lozenges of one strain, called CD2, to reduce painful mouth sores during cancer treatment, and probiotic gels or lozenges to support treatment of gum disease. Laboratory studies are exploring other properties, such as the ability of some strains to make GABA (gamma-aminobutyric acid), a chemical messenger in the nervous system, but these have not been shown to produce health benefits in people.
The most-studied use is gum disease (periodontitis), an infection and inflammation that gradually destroys the tissue and bone holding teeth in place. A 2026 systematic review found three small trials that added L. brevis, combined with another probiotic bacterium (Lactiplantibacillus plantarum), to a professional deep cleaning. When a dental professional placed the probiotic gel directly under the gums, the pockets around teeth became shallower and the gums reattached better than with cleaning alone, mainly in early-stage disease. Taking the probiotic by mouth gave inconsistent results, and benefit in advanced disease was unclear. The reviewers concluded that the trials were too few and too different to settle how useful it is. For oral mucositis, the painful mouth sores that radiation and chemotherapy for head and neck cancer often cause, one trial of 200 patients found that severe sores developed in about half of those using L. brevis CD2 lozenges compared with about three quarters of those on placebo, and more patients were able to complete their cancer treatment. That is a meaningful result, but it comes from a single trial and has not become standard care. Smaller studies of the same strain reported less gum bleeding and plaque in healthy adults and shorter-lasting sores after orthodontic braces were fitted. These findings belong to particular strains and products used in specific ways. A benefit seen with CD2 lozenges or a gum gel cannot be assumed for a different L. brevis product taken for digestion or general wellness. For most other uses, strong evidence that probiotics help is lacking.
L. brevis is sold as capsules, powders, lozenges and dissolving tablets, sometimes combined with other probiotic species, as in several of the trials. Probiotic amounts are counted in colony-forming units (CFU), an estimate of how many live bacteria a product contains, usually stated in billions. In the oral-health trials, the CD2 strain was given as lozenges or dissolving tablets several times a day; one orthodontic trial used 4 billion CFU after each meal. Lozenges dissolve slowly in the mouth, which is where these studies were trying to have an effect. There is no established dose for L. brevis, and a dose from a study applies only to the strain and product tested. Because the evidence is strain-specific, it helps to choose a product whose label names the exact strain rather than only the species.
Probiotics usually cause few side effects, and the small L. brevis CD2 trials reported no adverse effects from the product. Those trials were short and involved few people, and long-term safety data for probiotics in general are limited. The main serious concern with any probiotic is infection caused by the live microbes themselves. This is rare, and the risk is concentrated in people who are seriously ill or whose immune system is weakened.
People with a weakened immune system, such as from cancer treatment, an organ transplant or medicines that suppress immunity, and people who are seriously ill or in hospital, should check with their care team before taking L. brevis or any probiotic. The mucositis studies involved people with cancer, but under medical supervision. Probiotics should not be given to premature infants except under specialist direction: severe and sometimes fatal infections have been reported in premature infants given probiotics, and the U.S. Food and Drug Administration (FDA) has warned clinicians about this risk. Probiotics are mostly sold as dietary supplements, which do not need FDA approval before they are marketed, and some products have been found to contain microbes not listed on the label. A probiotic is not a substitute for dental or medical care, so ongoing gum bleeding, mouth sores or digestive symptoms are worth having assessed rather than treated alone, and taking a probiotic should not delay that visit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Levilactobacillus brevis, what you've noticed, or ask the community a question.